Surrogate markers in HIV disease

Journal of Antimicrobial Chemotherapy

Volumn 37, Issue SUPPL. B, 1996, Pages 161-170

  Peto, Tim ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CD4 ANTIGEN; MARKER; NEW DRUG; NUCLEOSIDE ANALOG;

CLINICAL TRIAL; CONFERENCE PAPER; DISEASE COURSE; DRUG EFFICACY; DRUG SCREENING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; META ANALYSIS; SURVIVAL;

EID: 0029789154     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/37.suppl_b.161     Document Type: Conference Paper

References (25)

1. Bieniasz, P. D., Ariyoshi, K., Bourelly, M. A., Bloor, S., Foxall, R. B., Harwood, E. C. et al. (1993). Variable relationship between proviral DNA load and infectious virus titre in the peripheral blood mononuclear cells of HIV-1-infected individuals. AIDS 7, 803-6.
2. Cardiac Arrhythmia Suppression Trial. (1989). Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrythmia suppression after myocardial infarction. New England Journal of Medicine 321, 409-12.
3. Choi, S. S., Lagakos, S. W., Schooley, R. T. & Volberding, P. A. (1993). CD4+ lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine. Annals of Internal Medicine 118, 674-80.
4. Concorde Coordinating Committee (1994). Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 343, 871-81.
5. Cooper, D. A., Gatell, J. M., Kroon, S., Clumeck, N., Millard, J., Goebel, F. D. et al. (1993). Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. New England Journal of Medicine 329, 297-303.
6. Darbyshire, J. H. & Aboulker, J. P. (1992). Didanosine for zidovudine-intolerant patients with HIV disease. Lancet 340, 1346-7.
7. Embretson, J., Zupancic, M., Ribas, J. L., Burke, A., Pacz, P., Tenner-Racz, K. et al. (1993). Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 362, 359-62.
8. Fahey, J. L., Taylor, J. M., Detels, R., Hofmann, B., Melmed, R., Nishanian, P. et al. (1990). The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. New England Journal of Medicine, 322, 166-72.
9. Fleming, T. R. (1994). Surrogate markers in AIDS and cancer trials. Statistics in Medicine 13, 1423-35.
10. Graziosi, C., Pantaleo, G., Demarest, J. F., Cohen, O. J., Vaccarezza, M., Butini, L. et al. (1993). HIV-1 infection in the lymphoid organs. AIDS 7, Suppl. 2, S53-8.
11. Ho, D. D., Neumann, A. U., Perelson, A. S., Chen, W., Leonard, J. M. & Markowitz, M. (1995). Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373, 123-6.
12. Jacobson, M. A., Bacchetti, P., Kolokathis, A., Chaisson, R. E., Szabo, S., Polsky, B. et al. (1991). Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine. British Medical Journal 302, 73-8.
13. Katzenstein, D. A., Winters, M., Bubp, J., Israelski, D., Winger, E. & Merigan, T. C. (1994). Quantitation of human immunodeficiency virus by culture and polymerase chain reaction in response to didanosine after long-term therapy with zidovudine. Journal of Infectious Diseases 169, 416-9.
14. Koenig, S., Brewah, Y. A., Jones, G. M., Leath, S., Boots, L. J., Davey, V. et al. (1995). Transfer of HIV-1-specific cytotoxic lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression. Nature Medicine 1, 330-6.
15. Lafeuillade, A., Tamalet, C., Pellegrino, P., de Micco, P., Vignoli, C. & Quilichini, R. (1994). Correlation between surrogate markers, viral load, and disease progression in HIV-1 infection. Journal of Acquired Immune Deficiency Syndromes 7, 1028-33.
16. Lagakos, S. W. (1993). Surrogate markers in AIDS clinical trials: conceptual basis, validation, and uncertainties. Clinical Infectious Diseases 16, Suppl. 1, S22-5.
17. Lange, J. M., de Wolf, F. & Goudsmit, J. (1989). Markers for progression in HIV infection. AIDS Suppl. 1, 3, S153-60.
18. Mellors, J. W., Kingsley, L. A., Rinaldo, C. R., Todd, J. A., Hoo, B. S., Kokka, R. P. (1995). Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Annals of Internal Medicine 122, 573-9.
19. Molina, J. M., Ferchal, F., Chevret, S., Barateau, V., Poirot, C., Morinet, F. et al. (1994). Quantification of HIV-1 virus load under zidovudine therapy in patients with symptomatic HIV infection: relation to disease progression. AIDS 8, 27-33.
20. Pantaleo, G., Graziosi, C., Demarest, J. F., Butini, L., Montroni, M., Fox, C. H. et al. (1993). HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 362, 355-8.
21. Phillips, A. N., Lee, C. A., Elford, J., Janossy, G., Timms, A., Bofill, M. et al. (1991). Serial CD4 lymphocyte counts and development of AIDS. Lancet 337, 389-92.
22. Prentice, R. L. (1989). Surrogate endpoints in clinical trials: definition and operational criteria. Statistics in Medicine 8, 431-40.
23. Saah, A. J., Munoz, A., Kuo, V., Fox, R., Kaslow, R. A., Phair, J. P. et al. (1992). Predictors of the risk of development of acquired immunodeficiency syndrome within 24 months among gay men seropositive for human immunodeficiency virus type 1: a report from the Multicenter AIDS Cohort Study. American Journal of Epidemiology 135, 1147-55.
24. Tsoukas, C. M. & Bernard, N. F. (1994). Markers predicting progression of human immunodeficiency virus-related disease. Clinical Microbiology Reviews, 7, 14-28.
25. Wei, X., Ghosh, S. K., Taylor, M. E., Johnson, V. A., Emini, E. A., Deutsch, P. et al. (1995). Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373, 117-22.